1. Home
  2. ZVRA vs GUG Comparison

ZVRA vs GUG Comparison

Compare ZVRA & GUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Zevra Therapeutics Inc.

ZVRA

Zevra Therapeutics Inc.

HOLD

Current Price

$11.88

Market Cap

562.2M

Sector

Health Care

ML Signal

HOLD

Logo Guggenheim Active Allocation Fund of Beneficial Interest

GUG

Guggenheim Active Allocation Fund of Beneficial Interest

HOLD

Current Price

$15.17

Market Cap

509.2M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
ZVRA
GUG
Founded
2006
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Trusts Except Educational Religious and Charitable
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
562.2M
509.2M
IPO Year
2015
2021

Fundamental Metrics

Financial Performance
Metric
ZVRA
GUG
Price
$11.88
$15.17
Analyst Decision
Strong Buy
Analyst Count
5
0
Target Price
$23.00
N/A
AVG Volume (30 Days)
1.1M
105.1K
Earning Date
05-06-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
159.21
N/A
EPS
0.74
N/A
Revenue
$106,470,000.00
N/A
Revenue This Year
$37.27
N/A
Revenue Next Year
$53.42
N/A
P/E Ratio
$16.04
N/A
Revenue Growth
350.91
N/A
52 Week Low
$7.16
$14.66
52 Week High
$15.04
$16.46

Technical Indicators

Market Signals
Indicator
ZVRA
GUG
Relative Strength Index (RSI) 52.37 40.58
Support Level $8.15 $14.75
Resistance Level $12.19 $16.17
Average True Range (ATR) 0.45 0.26
MACD 0.16 -0.02
Stochastic Oscillator 70.49 38.36

Price Performance

Historical Comparison
ZVRA
GUG

About ZVRA Zevra Therapeutics Inc.

Zevra Therapeutics Inc is a commercial-stage company with a late-stage pipeline committed to bringing life-changing therapeutics to people living with rare diseases. The Company is focused on expanding patient access, progressing its pipeline toward key milestones, and delivering meaningful outcomes for patients with unmet needs. The commercialization of its product, marketed in the United States for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a corporate foundation and demonstrates its ability to advance therapies from development to market.

About GUG Guggenheim Active Allocation Fund of Beneficial Interest

Guggenheim Active Allocation Fund is a diversified closed-end management investment company. The fund's investment objective is to maximize total return through a combination of current income and capital appreciation. The company invests in both fixed-income and other debt instruments selected from a variety of sectors and credit qualities, and may also invest in equities. It uses tactical asset allocation models to determine the optimal allocation of its assets between fixed-income and equity securities. A majority of its investments are made in corporate bonds and the rest in senior floating rate interests, asset-backed securities, preferred stocks, and other securities.

Share on Social Networks: